E.l.f. is one of only five public consumer companies out of 274 that has grown for 18 straight quarters and averaged at least 20% sales growth per quarter, chairman and CEO Tarang Amin noted during the Oakland, CA-based firm’s 1 August call to discuss Q1 results.
E.l.f. Cosmetics, Inc. continues pursuing white space opportunities in makeup, skin care and international as it raises its fiscal 2024 full-year sales growth projection to 37% to 39%, compared with the 22% to 24% forecasted previously.
The company booked $216.3m in sales in the first quarter ended 30 June, representing 76% growth over the same period...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
